[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488185":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":26,"studyPopulation":17,"armGroups":27,"interventions":40,"overallOfficials":17,"centralContacts":49,"locations":59,"responsibleParty":76,"collaborators":17,"id":80,"slug":17,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":81,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":17,"studyType":93,"phases":94,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":62,"whyStopped":17,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"University of Monastir","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"rate of blood pressure reduction","blood pressure reduction on 24 hours holter","90 days",[14],{"measure":15,"description":16,"timeFrame":12},"rate of lipid balance variation The secondary endpoint","variation in lipid reduction balance",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":24},"SINGLE",[25],"PARTICIPANT","This study will be carried out in 2 emergency departments (at the exit of the emergency room, patients included in the GR2 study) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital).\n\nAll the population will benifit of a biological assessment which include:\n\nComplete lipid profile, blood sugar, creatinine\n\none population will be randomized:\n\nThe population of patients with hypertension.\n\nFor patients in the hypertension group:\n\nA blood pressure with holter will be carried out for 24 hours .",[28,34],{"label":29,"type":30,"description":31,"interventionNames":32},"atherolive-drug","ACTIVE_COMPARATOR","The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherolive) will be prescribed at a dose of 400 mg, once a day for 3 months.",[33],"Drug: atherolive-drug",{"label":35,"type":36,"description":37,"interventionNames":38},"atherolive-placebo","PLACEBO_COMPARATOR","The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherolive-placebo) will be prescribed at a dose of 400 mg, once a day for 3 months.",[39],"Drug: Placebo Atherolive",[41,45],{"type":42,"name":29,"description":43,"armGroupLabels":44,"otherNames":17},"DRUG","The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.",[29],{"type":42,"name":46,"description":47,"armGroupLabels":48,"otherNames":17},"Placebo Atherolive","The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.",[35],[50,56],{"name":51,"role":52,"phone":53,"phoneExt":54,"email":55},"Nouira semir, Pr","CONTACT","73106046","216","semir.nouira@rns.tn",{"name":57,"role":52,"phone":53,"phoneExt":54,"email":58},"Bel Hadj Ali khaoula, MD","belhadjalikhaoula@yahoo.fr",[60],{"facility":61,"status":62,"city":63,"state":17,"zip":17,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"University Hospital Fattouma Bourguiba Monastir","RECRUITING","Monastir","Tunisia","TN",{"type":67,"coordinates":68},"Point",[69,70],10.82617,35.77799,{"lat":70,"lon":69},[73],{"name":74,"role":52,"phone":75,"phoneExt":17,"email":55},"Semir Nouira, Professor","0021673106046",{"type":77,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Pr. Semir Nouira","clinical proffesor","100488185",false,"NCT05636826","Olive Leaf Extracts in the Control of Hypertension","Efficacy of a Treatment Based on Olive Leaf Extracts in the Control of Cardiovascular Risk Factors:Hypertension","Atherolive","Inclusion Criteria:\n\n* patients over 18 years of age with:\n\nArterial hypertension (hypertension)\n\nExclusion Criteria:\n\n* . Exclusion criteria: None.","ALL","18 Years","95 Years",{"count":91,"type":92},500,"ESTIMATED","INTERVENTIONAL",[95,96],"PHASE2","PHASE3","This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital).\n\nPatients over 18 years of age with:\n\nArterial hypertension (hypertension).",[99],"Hypertension",[101],"hypertension","2024-11-05",{"date":104,"type":105},"2024-11-08","ACTUAL",{"date":107,"type":105},"2023-12-30",{"date":109,"type":92},"2025-12-30",{"name":5,"class":6},1]